ArticleJournal for immunotherapy of cancer2023

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.

Julius Strauss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.